Please Wait.....
Report
MEA Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2022-11-01 I 219 Pages I Data Bridge Market Research
The Middle East and Africa melanoma cancer diagnostics market is projected to register a substantial CAGR of 5.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Middle East and Africa Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Middle East and Africa melanoma cancer diagnostics market are:
- Increase in the prevalence of melanoma cancer
- Rising preference for preventive health check-ups
Market Players:
Some of the major players operating in the Middle East and Africa melanoma cancer diagnostics market are:
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- QIAGEN
- F. Hoffman-La Roche Ltd
- Abbott
- Myriad Genetics, Inc.
- VERISKIN INC.
- Illumina Inc
- bioMerieux SA
- NanoString
TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET 48
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 55
2.4 CURRENCY AND PRICING 55
2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
2.6 MULTIVARIATE MODELLING 60
2.7 PRODUCT TYPE LIFELINE CURVE 60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
2.9 DBMR MARKET POSITION GRID 62
2.10 MARKET END USER COVERAGE GRID 63
2.11 VENDOR SHARE ANALYSIS 64
2.12 SECONDARY SOURCES 65
2.13 ASSUMPTIONS 65
3 EXECUTIVE SUMMARY 66
4 PREMIUM INSIGHTS 68
4.1 PESTEL'S MODEL 69
4.2 PORTER'S FIVE FORCES MODEL 70
5 EPIDEMIOLOGY 71
6 INDUSTRY INSIGHTS 72
6.1 DEMOGRAPHIC TRENDS 72
6.2 KEY PRICING STRATEGIES 73
6.2.1 PRODUCT INNOVATION 73
6.2.2 CONSUMER AWARNESS 73
6.2.3 A VAST NETWORK OF DISTRIBUTION 73
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS 74
6.2.5 OTHERS 74
6.3 KEY PATIENT ENROLLMENT STRATEGIES 74
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS 74
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP 74
6.3.3 EDUCATE AND COMMUNICATE 75
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE 75
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES 75
7 MARKET OVERVIEW 77
7.1 DRIVERS 79
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER 79
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 80
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS 81
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER 82
7.2 RESTRAINTS 82
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 82
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS 83
7.3 OPPORTUNITIES 83
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT 83
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS 84
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 85
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 85
7.4 CHALLENGES 86
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS 86
7.4.2 RADIATION RISKS FROM IMAGING TESTS 86
8 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 87
8.1 OVERVIEW 88
8.2 INSTRUMENTS 91
8.2.1 IMAGING INSTRUMENTS 92
8.2.1.1 ULTRASOUND SYSTEMS 92
8.2.1.2 MRI SYSTEMS 92
8.2.1.3 CT SYSTEMS 92
8.2.1.4 OTHERS 93
8.2.2 BIOPSY INSTRUMENTS 93
8.2.3 PATHOLOGY-BASED INSTRUMENTS 93
8.2.3.1 PCR INSTRUMENTS 93
8.2.3.2 CELL PROCESSORS 93
8.2.3.3 SLIDE STAINING SYSTEMS 93
8.2.3.4 TISSUE PROCESSING SYSTEMS 94
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS 94
8.3 CONSUMABLES & ACCESSORIES 94
8.3.1 KITS 95
8.3.1.1 PCR KITS 95
8.3.1.2 NUCLEIC ACID ISOLATION KITS 95
8.3.1.3 DNA POLYMERASE KITS 95
8.3.1.4 OTHERS 96
8.3.2 PROBES 96
8.3.2.1 Q FISH 96
8.3.2.2 FLOW FISH 96
8.3.2.3 OTHERS 96
8.3.3 REAGENTS 96
8.3.3.1 ASSAYS 97
8.3.3.2 BUFFERS 97
8.3.3.3 PRIMERS 97
8.3.3.4 OTHERS 97
8.3.4 OTHER CONSUMABLES 97
8.4 OTHERS 97
9 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE 99
9.1 OVERVIEW 100
9.2 IMAGING TEST 103
9.2.1 ULTRASOUND 104
9.2.2 MRI 104
9.2.3 CHEST X-RAY 104
9.2.4 LYMPHOSCINTIGRAPHY 105
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN 105
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 105
9.2.7 OTHERS 105
9.3 BIOPSY 105
9.3.1 OPTICAL BIOPSY 106
9.3.2 EXCISIONAL BIOPSY 106
9.3.3 INCISIONAL BIOPSY 106
9.3.4 SHAVE BIOPSY 107
9.3.5 PUNCH BIOPSY 107
9.3.6 OTHERS 107
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS 107
9.4.1 S100 PROTEIN FAMILY BIOPSY 108
9.4.2 MELAN-A 108
9.4.3 PMEL/PMEL17/SILV/GP100 108
9.4.4 TYROSINASE 108
9.4.5 MITF 108
9.4.6 SM5-1 108
9.4.7 CSPG4/HMW-MAA 108
9.5 BIOMARKER TEST 109
9.5.1 BRAF MUTATION TEST 110
9.5.2 NRAS MUTATION TEST 110
9.5.3 CKIT TEST 110
9.5.4 OTHERS 110
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS 110
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS 111
9.8 OTHERS 112
10 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER 113
10.1 OVERVIEW 114
10.2 HOSPITALS 117
10.3 ASSOCIATED LABS 118
10.4 DIAGNOSTIC IMAGING CENTERS 118
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES 119
10.6 CANCER RESEARCH INSTITUTES 120
10.7 OTHERS 121
11 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 122
11.1 OVERVIEW 123
11.2 DIRECT TENDER 126
11.3 RETAIL SALES 126
12 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION 128
12.1 MIDDLE EAST AND AFRICA 129
12.1.1 SOUTH AFRICA 139
12.1.2 EGYPT 144
12.1.3 SAUDI ARABIA 149
12.1.4 U.A.E. 154
12.1.5 OMAN 159
12.1.6 KUWAIT 164
12.1.7 QATAR 169
12.1.8 BAHARAIN 174
12.1.9 REST OF MIDDLE EAST AND AFRICA 179
13 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 180
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 180
14 SWOT ANALYSIS 181
15 COMPANY PROFILE 182
15.1 ABBOTT 182
15.1.1 COMPANY SNAPSHOT 182
15.1.2 REVENUE ANALYSIS 182
15.1.3 COMPANY SHARE ANALYSIS 183
15.1.4 PRODUCT PORTFOLIO 183
15.1.5 RECENT DEVELOPMENTS 183
15.2 ILLUMINA, INC. 184
15.2.1 COMPANY SNAPSHOT 184
15.2.2 REVENUE ANALYSIS 184
15.2.3 COMPANY SHARE ANALYSIS 185
15.2.4 PRODUCT PORTFOLIO 185
15.2.5 RECENT DEVELOPMENT 185
15.3 BIOMERIEUX SA 186
15.3.1 COMPANY SNAPSHOT 186
15.3.2 REVENUE ANALYSIS 186
15.3.3 COMPANY SHARE ANALYSIS 187
15.3.4 PRODUCT PORTFOLIO 187
15.3.5 RECENT DEVELOPMENTS 187
15.4 THERMO FISHER SCIENTIFIC INC. 188
15.4.1 COMPANY SNAPSHOT 188
15.4.2 REVENUE ANALYSIS 188
15.4.3 COMPANY SHARE ANALYSIS 189
15.4.4 PRODUCT PORTFOLIO 189
15.4.5 RECENT DEVELOPMENT 189
15.5 F. HOFFMANN-LA ROCHE LTD. 190
15.5.1 COMPANY SNAPSHOT 190
15.5.2 REVENUE ANALYSIS 190
15.5.3 COMPANY SHARE ANALYSIS 191
15.5.4 PRODUCT PORTFOLIO 191
15.5.5 RECENT DEVELOPMENT 191
15.6 AGILENT TECHNOLOGIES, INC. 192
15.6.1 COMPANY PROFILE 192
15.6.2 REVENUE ANALYSIS 192
15.6.3 PRODUCT PORTFOLIO 193
15.6.4 RECENT DEVELOPMENT 193
15.7 AMLO BIOSCIENCES LIMITED 194
15.7.1 COMPANY PROFILE 194
15.7.2 PRODUCT PORTFOLIO 194
15.7.3 RECENT DEVELOPMENT 194
15.8 CASTLE BIOSCIENCES INC 195
15.8.1 COMPANY SNAPSHOT 195
15.8.2 REVENUE ANALYSIS 195
15.8.3 PRODUCT PORTFOLIO 196
15.8.4 RECENT DEVELOPMENT 196
15.9 DAMAE MEDICAL 197
15.9.1 COMPANY PROFILE 197
15.9.2 PRODUCT PORTFOLIO 197
15.9.3 RECENT DEVELOPMENT 197
15.10 DERMLITE. 198
15.10.1 COMPANY PROFILE 198
15.10.2 PRODUCT PORTFOLIO 198
15.10.3 RECENT DEVELOPMENTS 198
15.11 DERMASENSOR 199
15.11.1 COMPANY PROFILE 199
15.11.2 PRODUCT PORTFOLIO 199
15.11.3 RECENT DEVELOPMENT 199
15.12 DERMTECH 200
15.12.1 COMPANY SNAPSHOT 200
15.12.2 REVENUE ANALYSIS 200
15.12.3 PRODUCT PORTFOLIO 201
15.12.4 RECENT DEVELOPMENT 201
15.13 INIVATA LTD. 202
15.13.1 COMPANY PROFILE 202
15.13.2 PRODUCT PORTFOLIO 202
15.13.3 RECENT DEVELOPMENT 202
15.14 MICHAEL DIAGNOSTICS LTD 203
15.14.1 COMPANY SNAPSHOT 203
15.14.2 PRODUCT PORTFOLIO 203
15.14.3 RECENT DEVELOPMENT 203
15.15 MYRIAD GENETICS, INC. 204
15.15.1 COMPANY SNAPSHOT 204
15.15.2 REVENUE ANALYSIS 204
15.15.3 PRODUCT PORTFOLIO 205
15.15.4 RECENT DEVELOPMENT 205
15.16 NANOSTRING 206
15.16.1 COMPANY SNAPSHOT 206
15.16.2 REVENUE ANALYSIS 206
15.16.3 PRODUCT PORTFOLIO 207
15.16.4 RECENT DEVELOPMENT 207
15.17 NERACARE GMBH 208
15.17.1 COMPANY PROFILE 208
15.17.2 PRODUCT PORTFOLIO 208
15.17.3 RECENT DEVELOPMENT 208
15.18 SKIN ANALYTICS 209
15.18.1 COMPANY PROFILE 209
15.18.2 PRODUCT PORTFOLIO 209
15.18.3 RECENT DEVELOPMENT 209
15.19 SKYLINEDX 210
15.19.1 COMPANY PROFILE 210
15.19.2 PRODUCT PORTFOLIO 210
15.19.3 RECENT DEVELOPMENTS 210
15.20 VERISKIN INC. 211
15.20.1 COMPANY PROFILE 211
15.20.2 PRODUCT PORTFOLIO 211
15.20.3 RECENT DEVELOPMENTS 211
15.21 QIAGEN 212
15.21.1 COMPANY SNAPSHOT 212
15.21.2 REVENUE ANALYSIS 212
15.21.3 PRODUCT PORTFOLIO 213
15.21.4 RECENT DEVELOPMENT 213
15.22 QUEST DIAGNOSTICS INCORPORATED (2022) 214
15.22.1 COMPANY SNAPSHOT 214
15.22.2 REVENUE ANALYSIS 214
15.22.3 PRODUCT PORTFOLIO 215
15.22.4 RECENT DEVELOPMENTS 215
16 QUESTIONNAIRE 216
17 RELATED REPORTS 219
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security